1 |
18 fdg |
- |
- |
- |
- |
145 1件: 145 💬 |
2 |
Acetate |
Acetate |
- |
- |
- |
001 43件: 1 , 2 , 6 , 10, 13, 35, 40, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 227, 235, 265, 288, 298, 299 💬 |
3 |
Acth |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
013 5件: 13, 66, 145, 193, 222 💬 |
4 |
Adrenocorticotropin hormone |
- |
- |
- |
- |
145 1件: 145 💬 |
5 |
Cannabidiol |
Cannabidiol |
1件: D10915 D10915 💬 |
CNR1 2件: CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction 4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
006 17件: 6 , 8 , 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 226, 271 💬 |
6 |
Cannabidiol (cbd) |
Cannabidiol |
1件: D10915 D10915 💬 |
CNR1 2件: CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction 4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
006 6件: 6 , 140, 144, 145, 156, 158 💬 |
7 |
Cannabidiol oral solution |
Cannabidiol |
1件: D10915 D10915 💬 |
CNR1 2件: CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction 4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
140 4件: 140, 144, 145, 193 💬 |
8 |
Cbd |
- |
- |
- |
- |
002 11件: 2 , 6 , 8 , 13, 46, 140, 144, 145, 156, 158, 206 💬 |
9 |
Combination therapy with vigabatrin and prednisolone |
Prednisolone |
9件: D00472 D00472, D00535 D00535, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
ABAT 2件: ABAT, NR3C1 💬 |
Alanine, aspartate and glutamate metabolism 8件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
145 1件: 145 💬 |
10 |
Cosyntropin |
Tetracosactide |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
083 3件: 83, 113, 145 💬 |
11 |
Cosyntropin injectable suspension 1 mg/ml + vigabatrin |
Tetracosactide |
2件: D00284 D00284, D00535 D00535 💬 |
ABAT 2件: ABAT, MC2R 💬 |
Alanine, aspartate and glutamate metabolism 12件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, cAMP signaling pathway |
145 1件: 145 💬 |
12 |
Cosyntropin injectable suspension, 1 mg/ml |
Tetracosactide |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
145 1件: 145 💬 |
13 |
Decortin h |
- |
- |
- |
- |
066 3件: 66, 97, 145 💬 |
14 |
Fenfluramine |
Fenfluramine |
1件: D07945 D07945 💬 |
HTR2A 4件: HTR2A, HTR2B, HTR2C, SLC6A4 💬 |
Calcium signaling pathway 6件: Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
140 3件: 140, 144, 145 💬 |
15 |
Ganaxolone |
Ganaxolone |
1件: D04300 D04300 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
145 4件: 145, 152, 158, 206 💬 |
16 |
Gwp42003-p |
- |
- |
- |
- |
140 5件: 140, 144, 145, 156, 158 💬 |
17 |
Intravenous methylprednisolone |
Methylprednisolone |
6件: D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
013 2件: 13, 145 💬 |
18 |
Jbpos0101 |
JBPOS0101 |
- |
- |
- |
145 1件: 145 💬 |
19 |
M071754 |
- |
- |
- |
- |
145 1件: 145 💬 |
20 |
Melatonin |
Melatonin |
1件: D08170 D08170 💬 |
MTNR1A 2件: MTNR1A, MTNR1B 💬 |
Circadian entrainment 2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
006 11件: 6 , 8 , 13, 46, 49, 90, 97, 144, 145, 149, 202 💬 |
21 |
Methylprednisolone |
Methylprednisolone |
6件: D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
002 44件: 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 |
22 |
Modified atkins diet |
- |
- |
- |
- |
145 2件: 145, 157 💬 |
23 |
Null |
- |
- |
- |
- |
006 16件: 6 , 13, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 💬 |
24 |
Oral pednisolone |
- |
- |
- |
- |
145 1件: 145 💬 |
25 |
Oral prednisolone |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
049 2件: 49, 145 💬 |
26 |
Other: modified atkins diet |
- |
- |
- |
- |
145 1件: 145 💬 |
27 |
Prednisolone |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
011 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬 |
28 |
Pyridoxine |
Pyridoxine |
2件: D02179 D02179, D08454 D08454 💬 |
- |
- |
093 2件: 93, 145 💬 |
29 |
Pyridoxine plus prednisolone |
Prednisolone |
10件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02179 D02179, D03301 D03301, D08454 D08454 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
145 1件: 145 💬 |
30 |
Radiprodil |
Radiprodil |
- |
- |
- |
145 1件: 145 💬 |
31 |
Sabril |
- |
- |
- |
- |
145 1件: 145 💬 |
32 |
Sabril granules for oral use |
- |
- |
- |
- |
145 1件: 145 💬 |
33 |
Sabril sachets |
- |
- |
- |
- |
145 1件: 145 💬 |
34 |
Sabrilex |
- |
- |
- |
- |
145 1件: 145 💬 |
35 |
Sabril® |
- |
- |
- |
- |
145 1件: 145 💬 |
36 |
Soluble prednisolone tablets |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
145 1件: 145 💬 |
37 |
Spt3162 |
- |
- |
- |
- |
145 1件: 145 💬 |
38 |
Synacthen depot |
- |
- |
- |
- |
083 3件: 83, 145, 222 💬 |
39 |
Tetracosactide |
Tetracosactide |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
083 4件: 83, 113, 145, 222 💬 |
40 |
Tetracosactide acetate |
Acetate |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
083 2件: 83, 145 💬 |
41 |
Ucb3491 |
- |
- |
- |
- |
145 1件: 145 💬 |
42 |
Vgb-st |
- |
- |
- |
- |
145 1件: 145 💬 |
43 |
Vgb-st soluble tablets |
- |
- |
- |
- |
145 1件: 145 💬 |
44 |
Vigabatrin |
Vigabatrin |
1件: D00535 D00535 💬 |
ABAT 1件: ABAT 💬 |
Alanine, aspartate and glutamate metabolism 7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
145 2件: 145, 158 💬 |
45 |
Vigabatrin tablets |
Vigabatrin |
1件: D00535 D00535 💬 |
ABAT 1件: ABAT 💬 |
Alanine, aspartate and glutamate metabolism 7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
145 1件: 145 💬 |
46 |
Vigabatrin: vigabatrin new st formulation then sabril® |
Vigabatrin |
1件: D00535 D00535 💬 |
ABAT 1件: ABAT 💬 |
Alanine, aspartate and glutamate metabolism 7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
145 1件: 145 💬 |